Medication
Arixtra
DIN 02258056 · Aspen Pharmacare Canada Inc.
What it is
- Active ingredients
- Fondaparinux Sodium — 7.5 mg
- Form and route
- Solution · Subcutaneous
- Schedule
- PRESCRIPTION
- Authorised since
- 2008-04-17
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
Ontario Drug Benefit coverage
As of 31 July 2026Off-formulary interchangeable Part III-B
Ontario has designated this product interchangeable with a brand product, but it is not an ODB benefit — Part III-B, Off-Formulary Interchangeable. Ontario does not pay for it under the benefit list.
It may be funded through the Exceptional Access Program, which needs a patient-specific application from a prescriber and is decided case by case.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Products Ontario considers interchangeable
As of 31 July 2026Ontario groups these products together at 7.5mg/0.6mL Inj Sol-Pref Syr 0.6mL Pk (Preservative Free) and will substitute one for another at a pharmacy counter in Ontario.
- Fondaparinux Sodium Injection 02406896DR Reddy's Laboratories Ltd
This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Blood and blood-forming organs
- ATC code
- B01AX05
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of B01AX05, see the WHO ATC/DDD Index.
Recalls and safety alerts
Recall matching is not available yet.
RxMonitor does not yet match Health Canada recalls to individual products — that arrives in a later release. Nothing on this page should be read as confirming that this medication has not been recalled.